Intercept Pharmaceuticals, Inc. Stock
Stocks
ICPT
US45845P1084
Biotechnology & Medical Research
| 1 day | +0.21% |
| Manager | Title | Age | Since |
|---|---|---|---|
Vivek Devaraj
PSD | President | - | - |
Rocco Venezia
DFI | Director of Finance/CFO | 51 | 2023-10-31 |
Veruska di Sena
CTO | Chief Tech/Sci/R&D Officer | - | 2024-08-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Vivek Devaraj
CHM | Chairman | - | - |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 23-11-07 | Tender | Chief Executive Officer | 443,540 | 1.0609% | ||
| 23-11-07 | Tender | Director | 84,847 | 0.2029% | ||
| 23-11-07 | Tender | Chief Technology Officer | 214,739 | 0.5136% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.21% | +0.21% | - | - | 795M | |
| -0.71% | -0.29% | +56.45% | +107.18% | 54.54B | |
| -1.22% | +5.01% | +43.38% | +36.69% | 43.86B | |
| -1.43% | +3.47% | -15.83% | -20.48% | 22.63B | |
| -1.99% | -3.55% | -5.97% | +377.60% | 20.7B | |
| -1.27% | -0.27% | +15.25% | -36.57% | 15.84B | |
| -2.38% | -3.38% | +5.53% | -41.88% | 14.83B | |
| -1.70% | -1.68% | +24.79% | +172.92% | 13.1B | |
| -4.80% | +0.80% | +22.16% | - | 12.66B | |
| +0.29% | +5.10% | +75.82% | +105.33% | 11.56B | |
| Average | -1.51% | +2.14% | +24.62% | +87.60% | 23.3B | |
| Weighted average by Cap. | -1.44% | +1.41% | +30.06% | +86.73% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
